Camlin Fine Sciences Q3 Results Review - Operational Performance Below Expectation: Nirmal Bang

Nirmal Bang Report

Camlin Fine Sciences Ltd.’s Q3 FY23 Ebitda came in 11% below our estimate mainly on account of lower revenue growth due to correction in raw material prices, shutdown in Europe Diphenol facility for three weeks, signs of global slowdown and de-stocking at customers’ end.

Sequential revenue decline of ~20% was mainly volume driven on account of the aforementioned headwinds. Gross margin improved both on YoY as well as QoQ basis.

Higher share of downstream products, gradual easing of energy cost pressure in Europe and subsidy received to the tune of Rs 156 million during the quarter led to gross margin expansion.

Commercial production of composite vanillin plant commenced in January 2023. The management expects ~50% capacity utilisation in FY24 and overall revenue potential at peak utilisation remains Rs 8 billion, assuming constant pricing of Vanillin.

It highlighted that while the industry growth is ~4%, there is no other capacity addition in Vanillin. Camlin Fine Sciences' margin profile should improve from FY24 as catechol direct sales (at loss) should fall post Vanillin commercialisation.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.